First reported by pharmaphorum
GSK ends dementia alliance with Alector after setbacks
GSK ends Alector alliance as both lead assets fail
GSK has ended its five-year neuroscience partnership with Alector after latozinemab and nivisnebart both failed. The post GSK ends Alector alliance as both lead assets fail appeared first on European…
Read the full articleYou might also wanna read
Evidence suggests optimal LDL cholesterol range is 50 to 70 mg/dl for minimizing atherosclerosis risk
pubmed.ncbi.nlm.nih.gov·1h ago
uPAR-targeted CAR T cells show broad vulnerability in solid tumors with TP53/RAS mutations in preclinical models
cell.com·2h ago
Post-menopausal ovaries may shift identity and contribute to inflammation, mouse study suggests
newscientist.com·2h ago
Wireless forehead patch tracks brain-water shifts during sleep in home-based study
news-medical.net·2h ago
How modifier genes could neutralize severe genetic disorders
theatlantic.com·2h ago
B cells regulate exercise capacity through liver glutamate metabolism independent of immune function
cell.com·3h ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.